Physician profile
Fei Yu
NPI 1790727444
$1,341.79
in general payments reported to CMS, 2019-2025
14 companies · $339 in 2025
The $339 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $187 · 2020: $13.45 · 2021: $170 · 2022: $125 · 2023: $148 · 2024: $359 · 2025: $339.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $847.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $846.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $634.39 | 2019-2024 | Jardiance, Synjardy |
| Novartis Pharmaceuticals Corporation | $176.77 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $125.00 | 2022 | |
| Amgen INC. | $65.75 | 2024-2025 | Repatha, Repatha, Otezla |
| Amarin Pharma, INC. | $58.02 | 2020-2021 | |
| Pfizer INC. | $56.02 | 2024-2025 | |
| Lilly USA, LLC | $41.56 | 2024-2025 | Zepbound, Mounjaro |
| Glaxosmithkline, LLC. | $38.73 | 2025 | Shingrix |
| Tactile Systems Technology INC | $36.30 | 2019 | |
| Boston Scientific Corporation | $26.82 | 2023 | |
| Vertos Medical, INC. | $26.04 | 2019 | |
| Exact Sciences Corporation | $23.49 | 2025 | The Cologuard Plus Collection Kit |
| Kowa Pharmaceuticals America, INC. | $17.60 | 2025 | Zoryve |
| Astrazeneca Pharmaceuticals LP | $15.30 | 2024 | Farxiga |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fei Yu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.